RxDoctor Payments Data

Patricia Hatton, APRN

Gerontology · New Port Richey, FLNPI 1609451277

Payments from drug & device makers

$1,896in general payments, 2019–2025

Across 59 payments — averaging $32.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$497
  • AstraZeneca$289
  • Pfizer$181
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$172
  • AbbVie$170
  • Novo Nordisk$136
  • plus $451 from 11 others

What the payments were for

  • Food & beverage$1,896100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,896 in reported general payments places this provider in the 75th percentile of 714 gerontology providers in Florida.

See all gerontology providers in Florida

Medicare billing

Part B allowed, 2024
$3,971
Medicare patients
22
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm76$13,679
Fluticasone-SalmeterolFluticasone Propion/Salmeterol70$6,062
Gabapentin181$5,381
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm17$5,053
Albuterol Sulfate HfaAlbuterol Sulfate227$4,007
Atorvastatin Calcium503$3,651
Wixela InhubFluticasone Propion/Salmeterol35$3,442
Dabigatran EtexilateDabigatran Etexilate Mesylate11$3,049
Pantoprazole Sodium149$2,923
Levothyroxine Sodium199$2,518
Potassium Chloride70$1,973
Propranolol Hcl24$1,838
BreynaBudesonide/Formoterol Fumarate14$1,638
Nifedipine ErNifedipine27$1,602
Losartan Potassium314$1,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$170$96814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 714 gerontology providers in Florida.

Other gerontology in New Port Richey

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →